Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 3-25 , March 2006

Use of intravenous immunoglobulin G (IVIG)

References 

  1. Bruton O. Agammaglobulinemia. Pediatrics. 1952;9:722–727
  2. Imbach P, Barandun S, d'Apuzzo V, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1(8232):1228–1231
  3. Brambell F, WA H, IG M. A theorectical model of gammaglobulin catabolism. Nature. 1964;203:1352–1355
  4. Junghans RP, Anderson CL. The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor. Proceedings of the National Academy of Sciences of the United States of America. 1996;93(11):5512–5516
  5. Ghetie V, Hubbard JG, Kim JK, et al. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. European Journal of Immunology. 1996;26(3):690–696
  6. Ochs HD, Fischer SH, Lee ML, et al. Intravenous immunoglobulin home treatment for patients with primary immunodeficiency diseases. Lancet. 1986;1(8481):610–611
  7. Ashida ER, Saxon A. Home intravenous immunoglobulin therapy by self-administration. Journal of Clinical Immunology. 1986;6(4):306–309
  8. Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Annals of Internal Medicine. 1980;93(1):55–56
  9. Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338(8760):162–166
  10. Brandun S, Kistler P, Jenunet F, H I. intravenous administration of human gammaglobulin. Vox Sanguis. 1962;7:157–174
  11. Kroez M, Kanzy EJ, Gronski P, Dickneite G. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals. 2003;31(4):277–286
  12. Teeling JL, Bleeker WK, Rigter GM, et al. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages—studies in a rat model. British Journal of Haematology. 2001;112(4):1031–1040
  13. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 2000;95(5):1856–1861
  14. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood. 2001;98(4):1095–1099
  15. Roberton DM, Hosking CS. Use of methylprednisolone as prophylaxis for immediate adverse infusion reactions in hypogammaglobulinaemic patients receiving intravenous immunoglobulin: a controlled trial. Australian Paediatric Journal. 1988;24(3):174–177
  16. Lederman HM, Roifman CM, Lavi S. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. American Journal of Medicine. 1986;443–446
  17. Vyas GN, Perkins HA, Fudenberg HH. Anaphylactoid transfusion reactions associated with anti-IgA. Lancet. 1968;2(7563):312–315
  18. Vyas GN, Fudenberg HH. Isoimmune anti-IgA causing anaphylactoid transfusion reactions. New England Journal of Medicine. 1969;280(19):1073–1074
  19. Wells JV, Buckley RH, Schanfield MS, Fudenberg HH. Anaphylactic reactions to plasma infusions in patients with hypogammaglobulinemia and anti-IgA antibodies. Clinical Immunology and Immunopathology. 1977;8(2):265–271
  20. Wahn V, Good RA, Gupta S, et al. Evidence of persistent IgA/IgG circulating immune complexes associated with activation of the complement system in serum of a patient with common variable immune deficiency: anaphylactic reactions to intravenous gammaglobulin. Acta Pathologica, Microbiologica, et Immunologica Scandinavica—Supplement. 1984;284:49–58
  21. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. New England Journal of Medicine. 1986;314(9):560–564
  22. Bjorkander J, Hammarstrom L, Smith CI, et al. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-IgA antibodies. Journal of Clinical Immunology. 1987;7(1):8–15
  23. Eijkhout HW, van den Broek PJ, van der Meer JW. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Netherlands Journal of Medicine. 2003;61(6):213–217
  24. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Annals of Internal Medicine. 1994;121(4):259–262[see comment]
  25. Jayabose S, Mahmoud M, Levendoglu-Tugal O, et al. Corticosteroid prophylaxis for neurologic complications of intravenous immunoglobulin G therapy in childhood immune thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology. 1999;21(6):514–517
  26. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Annals of Hematology. 2004;83(10):661–665
  27. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA. 1996;276(19):1563–1567[see comment]
  28. Foster PR, Welch AG, McLean C, et al. Studies on the removal of abnormal prion protein by processes used in the manufacture of human plasma products. Vox Sanguinis. 2000;78(2):86–95
  29. Remington KM, Trejo SR, Buczynski G, et al. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sanguinis. 2004;87(1):10–18
  30. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. British Journal of Haematology. 2002;118(4):1187–1189[see comment]
  31. Cunningham-Rundles C, Siegal FP, Smithwick EM, et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Annals of Internal Medicine. 1984;101(4):435–439
  32. Rijkers GT, Sanders LA, Zegers BJ. Anti-capsular polysaccharide antibody deficiency states. Immunodeficiency. 1993;5(1):1–21
  33. Janeway CA, Rosen FS. The gamma globulins. IV. Therapeutic uses of gamma globulin. New England Journal of Medicine. 1966;275:826–831
  34. Liese JG, Wintergerst U, Tympner KD, Belohradsky BH. High- vs low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia. American Journal of Diseases of Children. 1992;146(3):335–339
  35. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet. 1987;1(8541):1075–1077
  36. Eijkhout HW, van Der Meer JW, Kallenberg CG. The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Annals of Internal Medicine. 2001;135:165–174
  37. Roifman CM, Schroeder H, Berger M, et al. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial. International Immunopharmacology. 2003;3(9):1325–1333
  38. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Seminars in Oncology. 1998;25(1):98–106
  39. Hargreaves RM, Lea JR, Griffiths H, et al. Immunological factors and risk of infection in plateau phase myeloma. Journal of Clinical Pathology. 1995;48(3):260–266
  40. Twomey JJ. Infections complicating multiple myeloma and chronic lymphocytic leukemia. Archives of Internal Medicine. 1973;132(4):562–565
  41. Griffiths H, Lea J, Bunch C, et al. Predictors of infection in chronic lymphocytic leukaemia (CLL). Clinical and Experimental Immunology. 1992;89(3):374–377
  42. Sklenar I, Schiffman G, Jonsson V. Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. Oncology. 1993;50:466–477
  43. Anonymous . Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. New England Journal of Medicine. 1988;319(14):902–907
  44. Chapel HM, Lee M, Hargreaves R, et al. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma [see comment]. Lancet. 1994;343(8905):1059–1063
  45. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia [see comment]. New England Journal of Medicine. 1991;325(2):81–86
  46. Anonymous . Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. The national institute of child health and human developments intravenous immunoglobulin study group [see comment]. New England Journal of Medicine. 1991;325(2):73–80
  47. Spector SA, Gelber RD, McGrath N, et al. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS clinical trials group [see comment]. New England Journal of Medicine. 1994;331(18):1181–1187
  48. Anonymous . Antiretroviral therapy and medical management of the human immunodeficiency virus-infected child. Working group on antiretroviral therapy: national pediatric hiv resource center [see comment] [erratum appears in Pediatr Infect Dis J Oct;12(10):19]. Pediatric Infectious Disease Journal. 1993;12(6):513–522
  49. Sullivan KM, Kopecky KJ, Jocom J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation [see comment]. New England Journal of Medicine. 1990;323(11):705–712
  50. Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clinical and Experimental Immunology. 1996;104(supplement 1):43–48
  51. Klaesson S, Ringden O, Ljungman P, Aschan J, Hagglund H, Winiarski J. Does high-dose intravenous immune globulin treatment after bone marrow transplantation increase mortality in veno-occlusive disease of the liver?. Transplantation. 1995;60(11):1225–1230
  52. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem-cell transplantation? A randomized, double-blind, dose effect, placebo-controlled, multicenter trial [see comment]. Annals of Internal Medicine. 2003;139(1):8–18
  53. Sullivan KM, Kansu E, Storer B, et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biology of Blood and Marrow Transplantation. 1998;4(1):20–26
  54. Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation. 2002;8(3):117–130
  55. Hayes-Lattin B, Seipel TJ, Gatter K, et al. Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation. American Journal of Hematology. 2004;75(3):142–145
  56. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation—a compassionate use experience. Bone Marrow Transplantation. 2000;25(2):161–165
  57. Alessandrino EP, Martinelli G, Canevari A, et al. Prompt response to high-dose intravenous immunoglobulins given as first-line therapy in post-transplant thrombotic thrombocytopenic purpura. Bone Marrow Transplantation. 2000;25(11):1217–1218
  58. Klumpp TR, Block CC, Caligiuri MA. Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine. 1992;71(2):73–83
  59. Hansen RJ, Balthasar JP. Mechanisms of IVIG action in immune thrombocytopenic purpura [Review] [70 refs]. Clinical Laboratory. 2004;50(3–4):133–140
  60. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases [see comment]. New England Journal of Medicine. 1999;340(3):227–228
  61. Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. Journal of Pediatric Hematology/Oncology. 2003;25(supplement 1):S14–S18
  62. Akilesh S, Petkova S, Sproule TJ, et al. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. Journal of Clinical Investigation. 2004;113(9):1328–1333
  63. Debre M, Bonnet MC, Fridman WH, et al. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993;342(8877):945–949
  64. Bayry J, Lacroix-Desmazes S, Delignat S, et al. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis and Rheumatism. 2003;48(12):3497–3502
  65. Frank MM, Basta M, Fries LF. The effects of intravenous immune globulin on complement-dependent immune damage of cells and tissues. Clinical Immunology and Immunopathology ;. 1992;62(1 Pt 2):S82–S86
  66. Imbach P, Wagner HP, Berchtold W, et al. Intravenous immunoglobulin versus oral corticosteroids in acute immune thrombocytopenic purpura in childhood. Lancet. 1985;2(8453):464–468
  67. Blanchette V, Imbach P, Andrew M, et al. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura [see comment]. Lancet. 1994;344(8924):703–707
  68. Cines DB, Blanchette VS. Immune thrombocytopenic purpura [see comment]. New England Journal of Medicine. 2002;346(13):995–1008
  69. Oates-Whitehead RM, Baumer JH, Haines L, et al. Intravenous immunoglobulin for the treatment of Kawasaki disease in children. Cochrane Database of Systematic Reviews. 2003;4:CD004000
  70. Furusho K, Sato K, Soeda T, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1983;2(8363):1359
  71. Furusho K, Kamiya T, Nakano H, et al. High-dose intravenous gammaglobulin for Kawasaki disease. Lancet. 1984;2(8411):1055–1058
  72. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. New England Journal of Medicine. 1986;315(6):341–347
  73. Engle MA, Fatica NS, Bussel JB, et al. Clinical trial of single-dose intravenous gamma globulin in acute Kawasaki disease. Preliminary report. American Journal of Diseases of Children. 1989;143(11):1300–1304
  74. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome [see comment]. New England Journal of Medicine. 1991;324(23):1633–1639
  75. Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome [see comment]. Lancet. 1993;342(8884):1385–1388
  76. Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile. Pharmacology and Therapeutics. 2004;102(3):177–193
  77. Dalakas MC. Intravenous immunoglobulin in autoimmune neuromuscular diseases [see comment]. JAMA. 2004;291(19):2367–2375
  78. Hughes RA, Raphael JC, Swan AV, Doorn PA. Intravenous immunoglobulin for Guillain–Barre syndrome. Cochrane Database of Systematic Reviews. 2004;1:CD002063
  79. Van Schaik IN, Winer JB, De Haan R, Vermeulen M. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database of Systematic Reviews. 2002;2:CD001797
  80. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis [see comment]. New England Journal of Medicine. 1993;329(27):1993–2000
  81. Ahmed AR, Dahl MV. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Archives of Dermatology. 2003;139(8):1051–1059
  82. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. Journal of the American Academy of Dermatology. 2001;44(6):1010–1024
  83. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression [see comment]. Archives of Dermatology. 2003;139(1):33–36
  84. Bachot N, Roujeau JC. Intravenous immunoglobulins in the treatment of severe drug eruptions. Current Opinion in Allergy and Clinical Immunology. 2003;3(4):269–274
  85. Braun-Moscovici Y, Furst DE. Immunoglobulin for rheumatic diseases in the twenty-first century: take it or leave it?. Current Opinion in Rheumatology. 2003;15(3):237–245
  86. Pildal J, Gotzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clinical Infectious Diseases. 2004;39(1):38–46
  87. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates [update of Cochrane Database Syst Rev 2004;(1):CD001239; PMID: 14973965][update of Cochrane Database Syst Rev 2000;(2):CD001239; PMID: 10796256]. Cochrane Database of Systematic Reviews. 2001;2:CD001239;002001

PII: S1521-6926(05)00033-2

doi: 10.1016/j.beha.2005.01.032

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 3-25 , March 2006

Article Tools